Jefferies Global Healthcare Conference
Logotype for Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals (ALNY) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Alnylam Pharmaceuticals Inc

Jefferies Global Healthcare Conference summary

18 Nov, 2026

AMVUTTRA launch and commercial execution

  • After 18 months, launch growth was substantial, but demand pace remained below expectations; only one-third of targeted physicians had prescribed AMVUTTRA.

  • Prescribers reached 2,000 after a ~25% field-force expansion; priorities are both deeper engagement and broader physician adoption, converting engagement into patient starts.

  • HELIOS-B evidence, reported early-treatment outcomes, and quarterly subcutaneous dosing support the product proposition; 90% of patients can access treatment within 10 miles through infusion clinics.

  • Commercial strategy remains focused on execution; a search is underway for a leader to drive AMVUTTRA growth and potential future launches, with an appointment expected in the near future.

U.S. payer access

  • AMVUTTRA has coverage for 99% of U.S. lives, with first-line access for ~75%; ~50% of current patients use fee-for-service Medicare, while Medicare Advantage represents ~35%.

  • UnitedHealth and Aetna policies affect ~10% and ~5% of lives, respectively; for 2027, no additional major Medicare Advantage policy changes were anticipated, though plans review policies annually.

  • Differentiating AMVUTTRA’s clinical profile is the stated focus for maintaining first-line access; physicians may appeal step edits when they consider it the most appropriate treatment.

340B reimbursement changes

  • Effective Jan. 1, 2027, 340B reimbursement is changing from ASP +6% to ASP -28%; institutions purchase AMVUTTRA at WAC -23.1%.

  • Contracting and discounts are planned to keep 340B purchases viable; contracting is expected to be in place by mid-December and does not affect ASP.

  • Institutions may remain in 340B with contracting, shift to WAC purchasing, or use alternate infusion sites; WAC purchasing would be positive for pricing, while 340B discounts would pressure net price.

  • The impact depends on institutional purchasing choices; guidance is planned for mid-February after five to six weeks of experience under the new rule, including key 340B assumptions.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Alnylam Pharmaceuticals